<DOC>
	<DOC>NCT02099682</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin</brief_summary>
	<brief_title>Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin</brief_title>
	<detailed_description>This is a special survey on long-term use (for up to 12 months) of lansoprazole (Takepron) to determine the incidence of adverse drug reactions in the routine clinical setting in patients receiving low-dose aspirin. The usual adult dosage is 15 mg of lansoprazole administered orally once daily.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>(1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring longterm use of lowdose aspirin (81324 mg once daily) as prophylaxis for thromboembolism (3) Patients taking lowdose oral aspirin (81324 mg once daily) at the start of administration of lansoprazole (including patients who start lowdose aspirin on the same day as the start of administration of lansoprazole) (1) Patients with gastric or duodenal ulcer (in the active [A1, A2] or healing [H1, H2] stage if assessed endoscopically) at the start of administration of lansoprazole (2) Patients with active upper gastrointestinal hemorrhage at the start of administration of lansoprazole (3) Patients with contraindications for lansoprazole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>